Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176

Next Previous
Trial Profile

A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AO 176 (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Malignant-mesothelioma; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Thyroid cancer
  • Focus Adverse reactions; First in man
  • Sponsors Arch Oncology

Most Recent Events

  • 21 Aug 2023 Status changed from active, no longer recruiting to completed.
  • 03 Aug 2022 Status changed from recruiting to active, no longer recruiting.
  • 03 Jul 2021 Planned number of patients changed from 132 to 183.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top